摘要
目的提高16型人乳头瘤病毒(HPV16)L1基因以杆状病毒为载体,在昆虫细胞中的表达水平,为研制预防性HPV疫苗奠定基础。
方法根据昆虫细胞密码子偏性对野生型HPV16L1基因进行改造,全基因合成密码子优化型HPV16L1基因,利用Bac-to-Bac表达系统获得重组杆状病毒,感染昆虫细胞Sf9和High Five。Western blot鉴定表达产物；电镜下观察病毒样颗粒形成。利用ELISA法评价HPV16L1基因的优化效果,并探讨L1蛋白在两种昆虫细胞中表达的最佳条件。
结果Sf9和High Five细胞的表达产物经Western blot检测,在相对分子质量56 kD处均出现HPV16L1的特异性条带；电镜下可见病毒样颗粒在两种昆虫细胞的核内形成；ELISA法结果显示密码子优化型HPV16L1基因的表达水平显著高于野生型(P<0.01)。High Five细胞表达的最佳条件为MOI=10,表达时相72 h,其L1蛋白表达量至少比Sf9细胞高3倍。
结论密码子优化技术确实能够促进HPV16L1蛋白的高效表达,而High Five细胞表现出的显著优势尤其值得关注。
Objective To enhance the expression level of human papillomavirus (HPV)16 L1 through Baculovirus Expression System, in order to lay a foundation of development of prophylactic HPV vaccines.
Methods We optimized the codon usage of wild type HPV16L1 gene according to the codon bias of insect cells and the full length optimized HPV16L1 gene was obtained by nucleotide synthesis. In order to infect both Sf9 and High Five insect cells, the recombinant baculovirus was obtained using Baculovirus Expression System. The expressed product was identified by Western blot; the virus-like particles (VLPs) of HPV 16 was confirmed by electron microscopy; and ELISA was used to evaluate the effect of the optimized gene as well as to determine the optimal expression conditions in both Sf9 and High Five insect cells.
Results The expressed protein, with a relative molecular mass of 56kD, showed specific reaction with HPV16L1 antiserum; The intranuclear VLPs of HPV16L1 were observed by electron microscopy; The result of ELISA indicated that the expression level of optimized HPV16L1 gene was significantly higher than the wild type; And the optimal expression condition for High Five cells was determined as MOI 10 and expression phase 72 hours, in which the L1 protein was expressed at least 3 times higher than that in Sf9 cells.
Conclusion Codon optimization could indeed enhance the expression level of HPV16L1 gene in insect cells; The significant advantage of High Five was worth attention.
引文
[1]Newall A T, Beutels P, Wood J G, et al. Cost-effectiveness analyses of human Papillomavirus vaccination. Lancet Infect Dis,2007,7(4)):289-296
[2]朗景和.子宫颈上皮内瘤变的诊断与治疗.中华妇产科杂志,2001,36(5)：261-263
[3]Munoz N, Bosch F X, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med,2003,348(6):518-527
[4]Zhou J, Sun X Y, Stenzel D J, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology,1991,185(1):251-257
[5]Widdce L E, Kahn J A, Using the new HPV vaccines in clinical practice. Cleve Clin J Med, 2006,3(10):929-935
[6]Steinbrook R. The potential of human papillomavirus vaccines. N Engl J Med,2006,354:1109-111
[7]Franco E L, Harper D M. Vaccination against human papillomavirus infection:a new paradigm in cervical cancer control. Vaccine,2005,23(17-18):2388-2394
[8]Villers E M, Fauquet C, Broker T R, et al. Classification of papillomaviruses. Virology,2004,324(1):17-27
[9]Dillner J. Mapping of linear epitopes of human papillomavirus type 16:the E1, E2, E4, E5, E6 and E7 open reading frames. lnt J Cancer,1990,46(4):703-711
[10]Embers M E, Budgeon L R, Pickel M, et al. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol, 2002,76:9798-9805
[11]Eileen M B. Human papillomavirus and cervical cancer. Clinical Microbiology Reviews,2003,16(1):1-17
[12]Rion G, Faver M, Jeannel D, et al. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet,1990,335(8699):1171-1174
[13]Altekruse S F, Lacey JV Jr, Brinton L A, et al. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma:Northeastern United States. Am J Obstet Gynecol,2003,188(3):657-663
[14]White W I, Wilson S D, Bonnez W. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol,1998,72(2):959-964
[15]Kirnbauer R, Taub J, Greensyone H, et al. Efficient self-assembly of human papillomavirus type 16L1 and L1-L2 into virus-like particles. J Virol,1993,67(12):6929-6936
[16]Roden R B, Hubbeet N L, Kimbauer R, et al. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol,1996,70(5):3298-3301
[17]Ziegert C, Wentzensen N, Vinokurova S, et al. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene, 2003,22(25):3977-3984
[18]Butler D, Collins C, Mabruk M, et al. Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features. J Pathol, 2000,192(4):502-510
[19]Hopman A H, Smedts F, Diqnef W, et al. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol,2004,202(1):23-33
[20]Munger K, Baldwin A, Edwards K M, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol,2004,78(21):11451-11460
[21]Scheffner M, Huibregtse J M, Viestra R D, et al. The HPV16E6 and E6-AP complex functions as a ubiquitin protein ligase in the ubiquitination of p53. Cell,1993,7(3):495-504
[22]Klingelhutz A J, Foster S A, McDougall J K. Telomerase activation by the E6 gene product of human papillomavirus type16. Nature,1996,380(6569):79-82
[23]Nakamura T M, Morin G B, Chapman K B, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science,1997,277(5328):955-959
[24]Pao C C, Tseng C J, Lin C Y, et al. Differential expression of telomerase activity in human cervical cancer and cervical intraepithelial neoplasia lesions. J Clin Oncol,1997,15(5):1932-1937
[25]Takakura M, Kyo S, Kanaya T, et al. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res,1998,58(7):1558-1561
[26]Veldman T, Liu X, Yuan H, et al. Human papillomavirusE6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci USA. 2003,100(14):8211-8216
[27]Betz B L, Strobeck M W, Reisman D N, et al. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of pl6ink4a and activation of RB. Oncogene, 2002,21(34):5193-5203
[28]Boulet G, Horvath C, Broeck D V, et al. Human papillomavirus:E6 and E7 oncogenes. Int J Biochem Cell Biol,2007,39(11):2006-2011
[29]Liu X, Clements A, Zhao K, et al. Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem,2006,281(1):578-586
[30]Tamura G, Yin J, Wang S, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas, J Natl Cancer Inst,2000,92(7):596-573
[31]Fields B N, Knipe D M, Howley P M, et al. Papillomaviridae:the viruses and their replication.3rd ed. Fields virology. Philadeiphia:Lippincott Raven Publishers,1996:947-948
[32]Webb E, Cox J, Edwards S. Cervical cancer-causing human papillomavirus have an alternative initiation site for the L1 protein. Virus Genes,2005,30(1):31-35
[33]Widdce L E, Kahn J A. Using the new HPV vaccines in clinical practice. Cleve Clin J Med, 2006,73(10):929-935
[34]Kimbauer R, Booy F, Cheng N et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA,1992,89(24):12180-12184
[35]Mao C, Koutsky L A, Ault K A, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia a randomized controlled trial. Obstet Gynecol,2006,107(1):18-27
[36]Harper D M, Francol E L, Wheeler C M, et al. HPV Vaccine Study group Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 follow-up from a randomized control trial. Lancet,2006,367(9518):1247-1255
[37]Zhang W, Carmichael J, Ferguson J. Expression of human papillomavirus type 16 L1 protein in Escherichia coli:denaturation, renaturation,, and self-assembly of virus-like particles in vitro.Virology, 1998,243(2):423-431
[38]Steinbrook R. The potential of human papillomavirus vaccines. N Engl J Med,2006,354:1109-111
[39]谢飞,刘红岩,董金蓉,等.HPV18晚期蛋白L1在毕赤酵母菌中的表达及鉴定.生物技术,2007,17：8-11
[40]Volpers C, Schirmacher P, Streeck R E, et al. Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology, 1994,200(2):504-512
[41]Luckow V A, Summes M D, High level expression of nonfused foreign genes with Autographa californica nuclear polyhedrosis virus expression rectors. Virology,1989,170(1):31-39
[42]Ailor E, Betenbaugh M J, Modifying secretion and post-translation processing in insect cells. Curr Opin
Biotechnol,1999,10(2):142-145
[43]Xiang Z Q, Pasquini S, Ertl H C. Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. J Immunol,1999,162(11):6716-6723
[44]Wang L, Hernandez-Alcoceba R, Shankar V. Prolonged and inducible transgene expression in the liver using gutless adenovirus:a potential therapy for liver cancer. Gastroenterology,2004,126(1):278-289
[45]Aires K A, Cianciarullo A M, Carneiro S M, et al. Production of human papillomavirus type 16L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol,2006,72(1):745-752
[46]Baud D, Benyacoub J, Revaz V, et al. Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium. Infect Immun,2004,72(2):750-756
[47]杨筱凤,陈宏伟,郑瑾,等.人乳头瘤病毒16L1-减毒志贺氏杆菌为载体疫苗的构建及免疫效应初步鉴定.病毒学报,2005,21(3)：198-203
[48]闫爱丽,郑瑾,来保长,等。人乳头瘤病毒18 L1型基因果蝇表达系统的构建和鉴定.陕西医学杂志,2007,36(8)：943-945
[49]Luckow V A, Lee S C, Barry G F, et al. Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli. J Virol 1993,67(8):4566-4579
[50]Smith M D. Production of human beta inferno in insect cell infected with baculovirus express vector. Mol Cell Biol,1983,3:2156-2163
[51]Shpaer E G. Constraints on codon context in Escherichia coli genes. Their possible role in modulating the efficiency of translation. J Mol Biol,1986,188(4):555-564
[52]Leder C, Kleinschmidt J A, et al. Enhancement of capsid gene expression:preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol, 2001,75(19):9201-9209
[53]Zhou J, Liu W J, Peng S W, et al. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol,1999,73(6):4972-4982
[54]Mossadegh N, Gissmann L, Muller M, et al. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology,2004,326(1):57-66.
[55]Liu W J, Zhao K N, Gao F G, et al. Polynucleotide viral vaccines:codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine,2001,20(5-6):862-869
[56]周玉柏,周玲,吴小兵,等.腺病毒载体介导密码子优化型HPV16L1基因在哺乳细胞中的高效表达及病毒样颗粒的装配.病毒学报,2006,22(2)：102-106
[57]宋敬东,王健伟,王敏,等。昆虫细胞偏爱密码子优化的HPV16L1基因在昆虫和哺乳动物细胞中的表达.中国病原生物学杂志,2007,(2)：247-251
[58]Gustafsson C, Govindarajan S, Minshull J, et al. Codon bias and heterologous protein expression. Trends Biotechnol.2004,22(7):346-353
[59]黄仕和.测定杆状病毒滴度方法的研究进展.微生物学免疫学进展,2007,35(2)：79-83
[60]王淼,宋国兴.人乳头瘤病毒的病毒样颗粒的生产方法.中国专利：02149970.5,2004-05-26
[61]Leder C, Kleinschmidt J A, Wiethe C, et al. Enhancement of capsid gene expression:preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol, 2001,75(19):9201-9209
[62]Prescott J, Liu L, Falck-Pedersen E. Sequence-mediated regulation of adenovirus gene expression by repression of mRNA accumulation. Mol Cell Biol,1997,17:2207-2216
[63]Tan W, Felber B K, Zolotukhin A S, et al. Efficient expression of the human papillomavirus type 16L1 protein in epithelial cells by using Rev and the Rev-responsive element of human immunodeficiency virus or the cis-acting transactivation element of simian retrovirus type. J Virol,1995,69:5607-5620
[64]Collier B, Oberg D, Zhao X, et al. Specific inactivation of inhibitory sequences in the 5'end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J Virol,2002,76(6):2739-2752
[65]Rollman E, Arnheim L, Collier B, et al. HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. Virology 2004,322(1):182-189
[66]Kool M, Ahrens C H, Vlak J M, et al. Replication of baculovirus DNA. J Gen Virol,1995,76 (Pt9):2103-2118
[67]Davis T R,Wickham T J,Mckenna K A, et al. Comparative recombinant protein production of eight insect cell lines. In Vitro Cell Dev Biol Anim.1993,29A(5):388-390
[68]Andrawiss M, Cervical Cancer vaccines available in 2007. Drug Discov Today,2005,10(14):949-950
[69]Dell G, Gaston K, Human papillomaviruses and their role in cervical cancer. Cell Mol Life Sci, 2001,58(12-13):1923-1942
[70]Roden R B, Yutzy W H 4th, Fallon R, et al. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology,2000,270(2):254-257
[71]Schiffman M, Kjaer S K. Chapter 2:Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr,2003,(31):14-19